Amgen (AMGN) Enterprise Value (2009 - 2026)
Amgen (AMGN) posted quarterly Enterprise Value of -$12.0 billion for Q1 2026, down 36.64% year-over-year from -$19.0 billion in Q1 2025, and down 31.87% quarter-over-quarter from -$9.1 billion in Q4 2025.
Amgen (AMGN) Enterprise Value (2009 - 2026) Analysis & Trends
Amgen's Enterprise Value history runs 18 years deep, the most recent figure standing at -$12.0 billion for Q1 2026.
- In Q1 2026, Enterprise Value fell 36.64% year-over-year to -$12.0 billion; the TTM figure through Mar 2026 stood at -$12.0 billion (down 36.64% YoY), while the FY2025 annual figure was -$9.1 billion, up 23.75% from the prior year.
- Enterprise Value for Q1 2026 stood at -$12.0 billion, down from -$9.1 billion in the prior quarter.
- The five-year high for Enterprise Value was -$6.5 billion in Q1 2022, with the low at -$34.7 billion in Q3 2023.
- The 5-year median for Enterprise Value is -$9.4 billion (2025), against an average of -$13.7 billion.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value slumped 382.9% in 2023, then jumped 74.03% in 2024.
- Amgen's Enterprise Value stood at -$9.3 billion in 2022, then decreased by 17.61% to -$10.9 billion in 2023, then decreased by 9.4% to -$12.0 billion in 2024, then grew by 23.75% to -$9.1 billion in 2025, then slumped by 31.87% to -$12.0 billion in 2026.
- Business Quant data shows AMGN's Enterprise Value at -$12.0 billion in Q1 2026, -$9.1 billion in Q4 2025, and -$9.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -20.76 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | -6.52 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -7.09 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -7.69 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | -4.90 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | -13.99 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -3.26 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -11.40 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -6.96 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.99 Bn |
| Mar 31, 2026 | -12.04 Bn |
| Dec 31, 2025 | -9.13 Bn |
| Sep 30, 2025 | -9.45 Bn |
| Jun 30, 2025 | -8.03 Bn |
| Mar 31, 2025 | -8.81 Bn |
| Dec 31, 2024 | -11.97 Bn |
| Sep 30, 2024 | -9.01 Bn |
| Jun 30, 2024 | -9.30 Bn |
| Mar 31, 2024 | -9.71 Bn |
| Dec 31, 2023 | -10.94 Bn |
| Sep 30, 2023 | -34.70 Bn |
| Jun 30, 2023 | -34.20 Bn |
| Mar 31, 2023 | -31.60 Bn |
| Dec 31, 2022 | -9.31 Bn |
| Sep 30, 2022 | -11.48 Bn |
| Jun 30, 2022 | -7.18 Bn |
| Mar 31, 2022 | -6.54 Bn |
| Dec 31, 2021 | -8.04 Bn |
| Sep 30, 2021 | -12.92 Bn |